Goodman SG, Aylward PE, Szarek M, et al. - In a pre-specified analysis of ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), researchers assessed the clinical benefit of adding alirocumab to statins in acute coronary syndrome (ACS) patients with prior coronary artery bypass grafting (CABG). Randomization to alirocumab or placebo, given subcutaneously every 2 weeks, of 18,924 patients 1 to 12 months post-ACS with high atherogenic lipoprotein levels despite high-intensity statin treatment was done. Participants were observed over a median duration of 2.8 years. The major adverse cardiovascular events (MACE) were assessed as the primary composite endpoint. The secondary endpoint was all-cause death. In patients with CABG preceding the ACS event, large absolute reductions in MACE and death were observed in correlation with alirocumab treatment in this study population comprising patients with recent ACS and raised atherogenic lipoproteins despite intensive statin therapy.